Print Page

Submit
Provided by NurseLinx.com
 
Search NurseLinx Archives 

September 03, 2010
Aging-related alterations in the extracellular matrix modulate the microenvironment and influence tumor progression - International Journal of Cancer
Sprenger CC et al. – Age is the greatest risk factor for the development of epithelial cancers. In this minireview, the auuthors will examine key extracellular matrix and matricellular components, their changes with aging, and discuss how these alterations might influence the subsequent progression of cancer in the aged host. Because of the tight correlation between advanced age and the prevalence of prostate cancer, the authors will use prostate cancer as the model throughout this minireview....
The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer - European Respiratory Review
Armour AA et al. – IPASS showed that EGFR mutation was the strongest predictor of improved progression–free survival (mutation–positive subgroup hazard ratio (HR) 0.48, 95% CI 0.36–0.64; mutation–negative subgroup HR 2.85, 95% CI 2.05–3.98 with gefitinib versus carboplatin/paclitaxel as first–line therapy for advanced NSCLC. Important lessons for the development of future personalised medicines are discussed....
Detailed Molecular Fingerprinting of Four New Anaplastic Thyroid Carcinoma Cell Lines and Their Use for Verification of RhoB as a Molecular Therapeutic Target - Journal of Clinical Endocrinology and Metabolism
Marlow LA et al. – The aim was to develop four ATC cell lines detailing genetic, molecular, and phenotypic characteristics and to test five classes of drugs on the cell lines to determine whether they inhibited cell proliferation in a RhoB–dependent fashion. Molecular descriptions of thyroid lines were matched to the originating tumors, setting a new standard for cell line characterization. Furthermore, suppressed RhoB is implicated as a molecular target for therapy against ATC because five classes of drugs up–regulate RhoB and inhibit growth dose–responsively....
Seeking Patient Feedback: An Important Dimension of Quality in Cancer Care - Journal of Nursing Care Quality
Richard ML et al. – A patient satisfaction survey was conducted with ambulatory cancer patients to identify areas that they consider priorities for change. Wait times and telephone contact with healthcare providers were the 2 areas of lowest satisfaction. Despite previous interventions to improve wait times, it is consistently the lowest ranked item for patient satisfaction. ...
Practical Approaches to Pharmacologic Management of Pain in Older Adults With Cancer - Oncology Nursing Forum
Brant JM et al. – Unrelieved pain can have a detrimental effect on older adults; conversely, overmedicating can lead to an increased risk of adverse events. With advancing age, physiologic changes alter the pharmacokinetic and pharmacodynamic properties of drugs by reducing their absorption, changing their distribution, and modifying their metabolism and elimination. Also, common comorbidities increase the risk of pharmacologic toxicity and narrow the therapeutic window. In addition, polypharmacy—an issue more common in older adults—increases the complexity of prescribing and risk of adverse events. Consequently, older adults require individualization of their pharmacotherapies. Healthcare providers should consider carefully the risks and benefits of nonsteroidal anti–inflammatory drugs, opioids, and adjuvants before initiating an analgesic trial. ...
Outcome Measures to Evaluate the Effectiveness of Pain Management in Older Adults With Cancer - Oncology Nursing Forum
Miaskowski C – Particularly in older adults, evaluation of functional outcomes provides a better indication of the effectiveness of pain management strategies than pain intensity ratings. Appropriate outcome measures for older adults in the outpatient setting include pain relief, physical functioning, emotional functioning, patients' ratings of global improvement and satisfaction with treatment, and symptoms and adverse effects associated with analgesic medications....
Management of sialoblastoma with surgery and brachytherapy - Pediatric Blood & Cancer
Shan XF et al. – Sialoblastoma is a rare congenital or perinatal salivary gland tumor with significant variability in histological appearance and biological behavior. The authors reported one case of sialoblastoma occurring in the parotid gland of an 18–month–old female. The tumor was excised with negative margins, and the sacrificed facial nerve was reconstructed with great auricular nerve graft. The tumor recurred 6 months after operation and was treated with 125I seed implant brachytherapy....
Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer - Medical Oncology
Hu CY et al. – Randomized trials conducted in the 1980s have established the effectiveness of 5–fluorouracil–based adjuvant chemotherapy in treating stage–III colon cancer. However, the initiation of adjuvant chemotherapy is just the first step for survival improvement. Little is known about the actual completion rate of such a therapy in the community. ...
Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: Current role and future perspectives - Cancer Treatment Reviews
Del Mastro L et al. – Luteinising hormone releasing hormone agonists (LH–RHa) induce ovarian suppression in premenopausal women that is usually reversible on cessation of therapy. They act by binding to pituitary LH–RH receptors, resulting in down regulation of receptors and subsequent suppression of luteinising hormone and estradiol. LH–RHa are effective in the treatment of advanced breast cancer in premenopausal women but their role as adjuvant treatment of early breast cancer is still controversial. ...
Alcohol and endometrial cancer risk in the NIH-AARP Diet and Health Study - International Journal of Cancer
Yang HP et al. – The results do not support that alcohol is a strong contributor to endometrial cancer risk, but slight risk increases may prevail among some users or for selected tumor characteristics....

More News...